When the price of nivolumab and ipilimumab reduced 80%, the probability of being cost-effective increased to 0% and 7.85% for nivolumab plus chemotherapy and 40.44% and 86.38% for nivolumab plus ipilimumab in overall and PD-L1-positive advanced ESCC patients, respectively. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.